ATLCAR.CD30.CCR4 cells

P1/2, N=31, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting

Pts are lymphodepleted with 3 days of bendamustine 70 mg/m 2 and fludarabine 30 mg/m 2...All pts had prior brentuximab vedotin and 11 pts had prior checkpoint inhibitors... CCR4.CD30.CAR-Ts are safe with promising efficacy even at the lowest DL in pts with r/r HL, suggesting that early tumor homing may improve antitumor activity. Our data serve as a proof of concept for future modifications of CAR-T cells to improve localization to tumor sites.

All patients receive lymphodepletion with 3 days of bendamustine 70 mg/m 2 and fludarabine 30 mg/m 2...All patients had received prior brentuximab vedotin...Two patients had grade 2 cytokine release syndrome (CRS) which resolved with tocilizumab, and 1 had self-limiting grade 1 CRS...Interestingly, responses are already seen at the lowest dose level, suggesting that early tumor homing driven by CCR4 may allow more fitted cells to better exploit their antitumor potential. Our data serve as a proof of concept for future modifications of CAR-T cells to improve their localization to disease sites.